Crinetics Pharmaceuticals reports successful Phase 3 results for paltusotine in treating acromegaly, with 56% of patients achieving normal IGF-1 levels.
Crinetics Pharmaceuticals reported successful Phase 3 results for its investigational oral drug, paltusotine, in treating acromegaly. In PATHFNDR-2 trial, 56% of patients on paltusotine achieved normal insulin-like growth factor 1 (IGF-1) levels, compared to 5% on a placebo. No serious adverse events were reported. Crinetics plans to submit a New Drug Application to the US FDA in the second half of 2024, aiming for a potential launch in 2025.
March 19, 2024
6 Articles